SCHEMBL4129733

SCHEMBL4129733

CN(NC(=O)c1cnn2c(-c3ccc(C#N)cc3F)c(-c3ccccc3C#N)cnc12)c1ccccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.37
PDE4D Q08499 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
GABRA1 P14867 4/20 0.35
GABRG2 P18507 4/20 0.35
GABRB3 P28472 4/20 0.35
GABRA3 P34903 4/20 0.35
GABRA5 P31644 2/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 2/20 0.35
EGLN2 Q96KS0 6/20 0.34
PKM P14618 1/20 0.34
THRB P10828 1/20 0.34
LMNA P02545 1/20 0.32
GRM5 P41594 1/20 0.32
GRM4 Q14833 1/20 0.32
EGLN1 Q9GZT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116611 0.92 GABRA1 (0.35) PDE4BPDE4DPDE4APDE4CGABRA1
SCHEMBL4108378 0.83 KDM4E (0.38) PDE4BPDE4DPDE4APDE4CGABRA1
SCHEMBL4125327 0.81 GRIN2B (0.37) PDE4BPDE4DPDE4APDE4CJAK2
SCHEMBL4112786 0.80 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4121225 0.72 JAK2 (0.36) PDE4BPDE4DPDE4APDE4CJAK2
SCHEMBL4120614 0.70 SMN1; SMN2 (0.35) PDE4BPDE4DPDE4APDE4CJAK2
SCHEMBL4118722 0.70 LMNA (0.39) LMNA
SCHEMBL4114117 0.70 KMT2A (0.38) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL1754896 0.68 ALDH1A1 (0.33) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4115866 0.68 GRIN2B (0.34) PDE4BPDE4DPDE4APDE4CJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD PDE4B 1938/4885PDE4D 2498/4885PDE4A 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.